

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT TO  
SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported) May 1, 2014**

---

**BECTON, DICKINSON AND COMPANY**

---

(Exact Name of Registrant as Specified in Its Charter)

---

**New Jersey**

---

(State or Other Jurisdiction of Incorporation)

---

**001-4802**

---

(Commission File Number)

---

**22-0760120**

---

(IRS Employer Identification No.)

---

**1 Becton Drive, Franklin Lakes, New Jersey**

---

(Address of Principal Executive Offices)

---

**07417-1880**

---

(Zip Code)

---

**(201) 847-6800**

---

(Registrant's Telephone Number, Including Area Code)

---

**N/A**

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

## ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On May 1, 2014, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its second fiscal quarter ending March 31, 2014. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”), as follows:

- **Revenues.** We present international and total revenue growth rates (for the total company and each of its segments and units, and for our safety-engineered devices) after eliminating the effect of foreign currency translation. We believe that these measures of revenue growth allow investors to better understand the underlying operating results of BD and facilitate comparisons to prior periods.
- **Earnings Per Share from Continuing Operations** We present diluted earnings per share from continuing operations (“EPS”) for the second quarter of fiscal year 2014, and EPS growth compared to the prior year period, after eliminating (i) the impact of foreign currency translation, (ii) charges relating to asset write-offs in our BD Biosciences segment, termination costs relating to the early termination of a distributor agreement in the Diagnostic segment and the gain from the sale of an equity investment (collectively, the “Second Quarter Items”), and (iii) the impact of both foreign currency translation and the Second Quarter Items”).

We also present EPS for the first six months of fiscal year 2014, and EPS growth compared to the prior year period, after eliminating (i) the impact of foreign currency translation, (ii) the impact of both foreign currency translation and the Second Quarter Items, and (iii) the impact of foreign currency translation, the Second Quarter Items and the first quarter fiscal year 2014 incremental impact of the medical device excise tax which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act.

We believe that eliminating the effect of foreign currency translation allows investors to better understand the underlying operating results of BD and facilitates comparisons to the prior year period. We also adjust for the Second Quarter Items because management does not view these items as part of our ordinary operations, and eliminating these items also facilitates comparisons to prior periods. Adjusting for the incremental impact of the medical device excise tax also facilitates comparisons to the prior year period as this tax was not in effect during the first quarter of fiscal year 2013.

We also present EPS for fiscal year 2013 after eliminating (i) a charge relating to an antitrust class action settlement, (ii) a charge relating to the verdict in BD’s litigation with Retractable Technologies, Inc., and (iii) a charge relating to non-cash pension settlements. We adjust for these charges because they are not considered by management to be part of our ordinary operations, and eliminating these items allows investors to better understand our EPS guidance for fiscal year 2014.

We also present estimated EPS guidance for fiscal year 2014 after adjusting for the Second Quarter Items, the anticipated impact of foreign currency translation and the one quarter of incremental impact from the medical device excise tax that BD will have in fiscal year 2014 compared to fiscal year 2013. Management believes eliminating these items allows investors to better understand our guidance in relation to fiscal year 2013 and the anticipated underlying performance of BD.

BD’s management uses each of these non-GAAP measures in its own evaluation of BD’s performance, particularly when comparing performance to past periods and to the performance of peer companies. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD’s financial results. Management believes the non-GAAP results provide a reasonable measure of BD’s underlying performance before the effects of items that are considered by management to be outside of BD’s underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD’s management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD’s net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD’s results.

---

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

Exhibit 99.1 Press release dated May 1, 2014, which is furnished pursuant to Item 2.02

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY  
(Registrant)

By: /s/ Gary DeFazio  
Gary DeFazio  
Vice President and Corporate Secretary

Date: May 1, 2014

99.1 Press release dated May 1, 2014, which is furnished pursuant to Item 2.02

1 Becton Drive  
Franklin Lakes, NJ 07417  
www.bd.com



Contact:

Monique N. Dolecki, Investor Relations – 201-847-5453  
Alyssa J. Zeff, Corporate Communications – 201-847-4358

**BD ANNOUNCES RESULTS FOR 2014 SECOND FISCAL QUARTER**

- Announces revenues of \$2.072 billion, an increase of 3.6 percent, or 5.1 percent on a foreign currency-neutral basis.
- Reports adjusted diluted earnings per share from continuing operations of \$1.53, an increase of 10.1 percent, or 15.8 percent on a foreign currency-neutral basis. Reported diluted earnings per share from continuing operations were \$1.45.

**Franklin Lakes, NJ (May 1, 2014)**– BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of \$2.072 billion for the second fiscal quarter ended March 31, 2014, representing an increase of 3.6 percent from the prior-year period, or 5.1 percent on a foreign currency-neutral basis.

“We are pleased with our solid second quarter and year-to-date results,” said Vincent A. Forlenza, Chairman, CEO and President. “Revenues were driven by the Medical segment and continued improvement in our Biosciences segment. This consistent performance demonstrates the breadth of the growth drivers across our businesses and regions, and highlights the diversity of our portfolio.”

**Second Quarter and Six-Month Fiscal 2014 Operating Results**

Reported diluted earnings per share from continuing operations for the second quarter were \$1.45 compared with \$1.39 in the prior-year period, representing a 4.3 percent increase. On a foreign currency-neutral basis, diluted earnings per share from continuing operations for the second quarter increased by 10.1 percent. Current quarter results include pre-tax charges for asset write-offs of \$20 million, or \$0.06 diluted earnings per share from continuing operations, and contract termination costs of \$11 million, or \$0.04 diluted earnings per share from continuing operations, partially offset by a pre-tax gain on investment of \$8 million, or \$0.03 diluted earnings per share from continuing operations. Excluding the net impact of these items, adjusted diluted earnings per share from

---

continuing operations were \$1.53. This represents an increase of 10.1 percent, or 15.8 percent on a currency-neutral basis.

For the six-month period ending March 31, 2014, diluted earnings per share from continuing operations were \$2.82, compared with \$2.74 in the prior-year period. This represents growth of 2.9 percent, or 9.1 percent on a currency-neutral basis. Excluding the first quarter incremental impact of the medical device excise tax, which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act, adjusted diluted earnings per share from continuing operations were \$2.94 compared with \$2.74 in the prior-year period. This represents growth of 7.3 percent, or 13.5 percent on a currency-neutral basis.

### **Segment Results**

In the BD Medical segment, worldwide revenues for the quarter were \$1.116 billion, representing an increase of 5.1 percent compared with the prior-year period, or an increase of 6.3 percent on a foreign currency-neutral basis. The segment's revenue growth reflects strong sales in the Diabetes Care unit and solid sales in the Medical Surgical Systems and Pharmaceutical Systems units.

For the six-month period ended March 31, 2014, BD Medical revenues increased 6.6 percent, or 7.4 percent on a currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$653 million, representing a decrease of 0.9 percent compared with the prior-year period, or an increase of 1.0 percent on a foreign currency-neutral basis. Solid sales in the Preanalytical Systems unit were partially offset by ongoing softness in Women's Health and Cancer in the U.S.

For the six-month period ended March 31, 2014, BD Diagnostics revenues increased 1.1 percent, or 2.6 percent on a currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were \$302 million, representing an increase of 8.2 percent compared with the prior-year period, or an increase of 10.2 percent on a foreign currency-neutral basis. The segment's growth was driven by continued strength in emerging markets, solid instrument placements, a favorable comparison to the prior year and a timing of orders.

For the six-month period ended March 31, 2014, BD Biosciences revenues increased 6.8 percent, or 8.0 percent on a currency-neutral basis.

### **Geographic Results**

Second quarter revenues in the U.S. of \$826 million represent an increase of 0.2 percent over the prior-year period. Revenues outside of the U.S. were \$1.246 billion, representing an increase of 5.9 percent compared with the prior-year period, or an increase of 8.5 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and sales of safety-engineered products.

For the six-month period ended March 31, 2014, revenues in the U.S. were \$1.675 billion, representing an increase of 1.3 percent compared with the prior-year period. Revenues outside of the

---

U.S. were \$2.412 billion, representing an increase of 7.3 percent when compared with the prior-year period, or 9.2 percent on a foreign currency-neutral basis.

#### **Fiscal 2014 Outlook for Full Year**

The Company reaffirms its previously communicated currency-neutral revenue guidance range of 4.5 to 5.0 percent. On a reported basis, the Company expects revenue growth of 4.0 to 4.5 percent. The Company is raising its previous guidance for diluted earnings per share from continuing operations for the full fiscal year 2014 to be between \$6.14 and \$6.17, or \$6.22 and \$6.25 excluding the impact of the previously mentioned second quarter adjustments. This represents growth of 7.0 to 7.5 percent over 2013 adjusted diluted earnings per share of \$5.81. On a foreign currency-neutral basis, adjusted diluted earnings per share are expected to grow about 10.0 to 10.5 percent, or 11.0 to 11.5 percent excluding the incremental impact of the medical device tax. The Company plans to repurchase, subject to market conditions, about \$450 million of its common stock in fiscal year 2014.

#### **Conference Call Information**

A conference call regarding BD's second quarter results will be broadcast live on BD's website, [www.bd.com/investors](http://www.bd.com/investors), along with related slides, at 8:00 a.m. (ET) Thursday, May 1<sup>st</sup>, 2014. The conference call will be available for replay on BD's website, [www.bd.com/investors](http://www.bd.com/investors), or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Thursday, May 8<sup>th</sup>, 2014, confirmation number 24652897.

#### **Non-GAAP Financial Measures/Financial Tables**

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

#### **About BD**

BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are nearly 30,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit [www.bd.com](http://www.bd.com).

\*\*\*

*This press release, including the section entitled "Fiscal 2014 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: potential cuts in healthcare spending by the U.S. government as part of deficit reduction measures which could result in reduced demand for our product or downward*



---

*pricing pressure; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; our ability to successfully integrate any businesses we acquire; the adverse impact of cyber-attacks on our information systems; competitive factors; pricing and market pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.*

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in millions, except share and per share data)

	Three Months Ended March 31,		
	2014	2013	% Change
REVENUES	\$ 2,072	\$ 2,000	3.6
Cost of products sold	1,019	982	3.7
Selling and administrative	525	515	2.0
Research and development	147	122	20.0
TOTAL OPERATING COSTS AND EXPENSES	1,690	1,619	4.4
OPERATING INCOME	381	381	0.1
Interest income	10	12	(18.4)
Interest expense	(33)	(35)	(4.7)
Other income, net	5	2	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	363	360	0.8
Income tax provision	76	84	(9.9)
INCOME FROM CONTINUING OPERATIONS	287	276	4.0
INCOME (LOSS) FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION (BENEFIT) OF \$0 AND \$(1), RESPECTIVELY	—	—	NM
NET INCOME	\$ 287	\$ 276	4.2
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 1.48	\$ 1.42	4.2
Income (loss) from discontinued operations	\$ —	\$ —	—
Net income	\$ 1.48	\$ 1.42	4.2
Diluted:			
Income from continuing operations	\$ 1.45	\$ 1.39	4.3
Income (loss) from discontinued operations	\$ —	\$ —	—
Net income	\$ 1.45	\$ 1.39	4.3
AVERAGE SHARES OUTSTANDING (in thousands)			
Basic	193,609	194,609	
Diluted	197,488	198,143	

NM - Not Meaningful

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in millions, except share and per share data)

	Six Months Ended March 31,		
	2014	2013	% Change
REVENUES	\$ 4,086	\$ 3,901	4.8
Cost of products sold	1,999	1,876	6.5
Selling and administrative	1,056	1,010	4.5
Research and development	273	241	13.4
TOTAL OPERATING COSTS AND EXPENSES	<u>3,327</u>	<u>3,127</u>	<u>6.4</u>
OPERATING INCOME	759	773	(1.8)
Interest income	24	20	19.4
Interest expense	(67)	(70)	(4.5)
Other income, net	<u>6</u>	<u>3</u>	<u>NM</u>
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	722	726	(0.6)
Income tax provision	<u>164</u>	<u>180</u>	<u>(9.0)</u>
INCOME FROM CONTINUING OPERATIONS	558	546	2.2
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF \$0 AND \$215, RESPECTIVELY	<u>—</u>	<u>355</u>	<u>NM</u>
NET INCOME	<u>\$ 558</u>	<u>\$ 901</u>	<u>(38.0)</u>
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 2.88	\$ 2.79	3.2
Income from discontinued operations	\$ —	\$ 1.81	NM
Net income	<u>\$ 2.88</u>	<u>\$ 4.61</u>	<u>(37.5)</u>
Diluted:			
Income from continuing operations	\$ 2.82	\$ 2.74	2.9
Income from discontinued operations	\$ —	\$ 1.78	NM
Net income	<u>\$ 2.82</u>	<u>\$ 4.53</u>	<u>(37.7)</u>
AVERAGE SHARES OUTSTANDING (in thousands)			
Basic	193,909	195,528	
Diluted	<u>197,998</u>	<u>199,068</u>	

NM - Not Meaningful

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in millions)

	Three Months Ended March 31,		
	2014	2013	% Change
<b>BD MEDICAL</b>			
United States	\$ 434	\$ 412	5.2
International	682	650	5.0
TOTAL	<u>\$1,116</u>	<u>\$1,062</u>	<u>5.1</u>
<b>BD DIAGNOSTICS</b>			
United States	\$ 301	\$ 322	(6.4)
International	352	337	4.5
TOTAL	<u>\$ 653</u>	<u>\$ 659</u>	<u>(0.9)</u>
<b>BD BIOSCIENCES</b>			
United States	\$ 90	\$ 89	1.4
International	212	191	11.4
TOTAL	<u>\$ 302</u>	<u>\$ 279</u>	<u>8.2</u>
<b>TOTAL REVENUES</b>			
United States	\$ 826	\$ 824	0.2
International	1,246	1,177	5.9
TOTAL	<u>\$2,072</u>	<u>\$2,000</u>	<u>3.6</u>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in millions)

	Six Months Ended March 31,		
	2014	2013	% Change
<b>BD MEDICAL</b>			
United States	\$ 875	\$ 838	4.5
International	<u>1,304</u>	<u>1,208</u>	<u>8.0</u>
TOTAL	<u>\$2,180</u>	<u>\$2,045</u>	<u>6.6</u>
<b>BD DIAGNOSTICS</b>			
United States	\$ 622	\$ 643	(3.2)
International	<u>703</u>	<u>668</u>	<u>5.2</u>
TOTAL	<u>\$1,325</u>	<u>\$1,311</u>	<u>1.1</u>
<b>BD BIOSCIENCES</b>			
United States	\$ 177	\$ 173	2.3
International	<u>404</u>	<u>371</u>	<u>8.9</u>
TOTAL	<u>\$ 581</u>	<u>\$ 544</u>	<u>6.8</u>
<b>TOTAL REVENUES</b>			
United States	\$1,675	\$1,654	1.3
International	<u>2,412</u>	<u>2,247</u>	<u>7.3</u>
TOTAL	<u>\$4,086</u>	<u>\$3,901</u>	<u>4.8</u>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended March 31,  
(Unaudited; Amounts in millions)

	United States		
	<u>2014</u>	<u>2013</u>	<u>% Change</u>
<b>BD MEDICAL</b>			
Medical Surgical Systems	\$240	\$236	1.9
Diabetes Care	118	107	10.3
Pharmaceutical Systems	76	70	8.8
<b>TOTAL</b>	<u>\$434</u>	<u>\$412</u>	<u>5.2</u>
<b>BD DIAGNOSTICS</b>			
Preanalytical Systems	\$163	\$162	0.7
Diagnostic Systems	138	160	(13.6)
<b>TOTAL</b>	<u>\$301</u>	<u>\$322</u>	<u>(6.4)</u>
<b>BD BIOSCIENCES</b>	<u>\$ 90</u>	<u>\$ 89</u>	<u>1.4</u>
<b>TOTAL UNITED STATES</b>	<u>\$826</u>	<u>\$824</u>	<u>0.2</u>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended March 31, (continued)  
(Unaudited; Amounts in millions)

	International				
	2014	2013	Reported	% Change	
				FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 311	\$ 303	2.6	6.3	(3.7)
Diabetes Care	133	125	6.2	10.5	(4.3)
Pharmaceutical Systems	238	221	7.6	5.9	1.7
<b>TOTAL</b>	<b>\$ 682</b>	<b>\$ 650</b>	<b>5.0</b>	<b>7.0</b>	<b>(2.0)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 179	\$ 168	6.7	10.2	(3.5)
Diagnostic Systems	173	169	2.3	6.0	(3.7)
<b>TOTAL</b>	<b>\$ 352</b>	<b>\$ 337</b>	<b>4.5</b>	<b>8.1</b>	<b>(3.6)</b>
<b>BD BIOSCIENCES</b>	<b>\$ 212</b>	<b>\$ 191</b>	<b>11.4</b>	<b>14.3</b>	<b>(2.9)</b>
<b>TOTAL INTERNATIONAL</b>	<b>\$1,246</b>	<b>\$1,177</b>	<b>5.9</b>	<b>8.5</b>	<b>(2.6)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended March 31, (continued)  
(Unaudited; Amounts in millions)

	2014	2013	Total		
			Reported	FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 551	\$ 539	2.3	4.4	(2.1)
Diabetes Care	251	232	8.1	10.4	(2.3)
Pharmaceutical Systems	314	291	7.9	6.6	1.3
<b>TOTAL</b>	<b>\$1,116</b>	<b>\$1,062</b>	<b>5.1</b>	<b>6.3</b>	<b>(1.2)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 342	\$ 330	3.7	5.5	(1.8)
Diagnostic Systems	311	329	(5.5)	(3.6)	(1.9)
<b>TOTAL</b>	<b>\$ 653</b>	<b>\$ 659</b>	<b>(0.9)</b>	<b>1.0</b>	<b>(1.9)</b>
<b>BD BIOSCIENCES</b>	<b>\$ 302</b>	<b>\$ 279</b>	<b>8.2</b>	<b>10.2</b>	<b>(2.0)</b>
<b>TOTAL REVENUES</b>	<b>\$2,072</b>	<b>\$2,000</b>	<b>3.6</b>	<b>5.1</b>	<b>(1.5)</b>



BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL REVENUE INFORMATION  
 REVENUES BY BUSINESS SEGMENTS AND UNITS  
 Six Months Ended March 31,  
 (Unaudited; Amounts in millions)

	United States		
	2014	2013	% Change
<b>BD MEDICAL</b>			
Medical Surgical Systems	\$ 502	\$ 485	3.6
Diabetes Care	239	219	9.3
Pharmaceutical Systems	133	134	(0.4)
<b>TOTAL</b>	<b>\$ 875</b>	<b>\$ 838</b>	<b>4.5</b>
<b>BD DIAGNOSTICS</b>			
Preanalytical Systems	\$ 335	\$ 329	1.7
Diagnostic Systems	288	314	(8.3)
<b>TOTAL</b>	<b>\$ 622</b>	<b>\$ 643</b>	<b>(3.2)</b>
<b>BD BIOSCIENCES</b>	<b>\$ 177</b>	<b>\$ 173</b>	<b>2.3</b>
<b>TOTAL UNITED STATES</b>	<b>\$1,675</b>	<b>\$1,654</b>	<b>1.3</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Six Months Ended March 31, (continued)  
(Unaudited; Amounts in millions)

	International				
	2014	2013	Reported	% Change	
				FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 627	\$ 590	6.4	9.2	(2.8)
Diabetes Care	275	256	7.5	11.0	(3.5)
Pharmaceutical Systems	402	362	11.0	8.5	2.5
<b>TOTAL</b>	<b>\$1,304</b>	<b>\$1,208</b>	<b>8.0</b>	<b>9.4</b>	<b>(1.4)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 355	\$ 336	5.7	8.2	(2.5)
Diagnostic Systems	348	332	4.7	8.0	(3.3)
<b>TOTAL</b>	<b>\$ 703</b>	<b>\$ 668</b>	<b>5.2</b>	<b>8.1</b>	<b>(2.9)</b>
<b>BD BIOSCIENCES</b>	<b>\$ 404</b>	<b>\$ 371</b>	<b>8.9</b>	<b>10.6</b>	<b>(1.7)</b>
<b>TOTAL INTERNATIONAL</b>	<b>\$2,412</b>	<b>\$2,247</b>	<b>7.3</b>	<b>9.2</b>	<b>(1.9)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Six Months Ended March 31, (continued)  
(Unaudited; Amounts in millions)

	2014	2013	Total		
			Reported	FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$1,130	\$1,075	5.2	6.7	(1.5)
Diabetes Care	514	475	8.3	10.2	(1.9)
Pharmaceutical Systems	535	496	7.9	6.1	1.8
<b>TOTAL</b>	<b>\$2,180</b>	<b>\$2,045</b>	<b>6.6</b>	<b>7.4</b>	<b>(0.8)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 690	\$ 665	3.7	5.0	(1.3)
Diagnostic Systems	636	646	(1.6)	0.1	(1.7)
<b>TOTAL</b>	<b>\$1,325</b>	<b>\$1,311</b>	<b>1.1</b>	<b>2.6</b>	<b>(1.5)</b>
<b>BD BIOSCIENCES</b>	<b>\$ 581</b>	<b>\$ 544</b>	<b>6.8</b>	<b>8.0</b>	<b>(1.2)</b>
<b>TOTAL REVENUES</b>	<b>\$4,086</b>	<b>\$3,901</b>	<b>4.8</b>	<b>5.9</b>	<b>(1.1)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
SAFETY REVENUES  
(Unaudited; Amounts in millions)

	Three Months Ended March 31,				
	2014	2013	Reported	% Change FXN	FX Impact
<b>TOTAL SAFETY REVENUES</b>					
United States	\$ 287	\$ 287	—	—	—
International	244	227	7.3	11.2	(3.9)
<b>TOTAL</b>	<b>\$ 531</b>	<b>\$ 514</b>	<b>3.2</b>	<b>4.9</b>	<b>(1.7)</b>
<b>BY SEGMENT</b>					
BD Medical	\$ 263	\$ 256	2.7	4.4	(1.7)
BD Diagnostics	268	258	3.7	5.5	(1.8)
<b>TOTAL</b>	<b>\$ 531</b>	<b>\$ 514</b>	<b>3.2</b>	<b>4.9</b>	<b>(1.7)</b>
	Six Months Ended March 31,				
	2014	2013	Reported	% Change FXN	FX Impact
<b>TOTAL SAFETY REVENUES</b>					
United States	\$ 602	\$ 578	4.1	4.1	—
International	486	447	8.7	11.6	(2.9)
<b>TOTAL</b>	<b>\$1,088</b>	<b>\$1,026</b>	<b>6.1</b>	<b>7.3</b>	<b>(1.2)</b>
<b>BY SEGMENT</b>					
BD Medical	\$ 548	\$ 508	7.8	9.1	(1.3)
BD Diagnostics	540	517	4.4	5.6	(1.2)
<b>TOTAL</b>	<b>\$1,088</b>	<b>\$1,026</b>	<b>6.1</b>	<b>7.3</b>	<b>(1.2)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
FY2014 Quarter-to-Date Reconciliation of Non-GAAP Financial Measures  
(Unaudited)

	Three Months Ended March 31,						
	<u>2014</u>	<u>2013</u>	<u>Growth</u>	<u>Foreign Currency Translation</u>	<u>Foreign Currency Neutral Change</u>	<u>Growth %</u>	<u>Foreign Currency Neutral Growth %</u>
Reported Diluted Earnings per Share from Continuing Operations	\$ 1.45	\$ 1.39	\$ 0.06	\$ (0.08)	\$ 0.14	4.3%	10.1%
Write-off of capitalized product software and, to a lesser extent, fixed assets primarily resulting from the discontinuance of an instrument product development program in the Biosciences segment (\$20 million or \$12 million after-tax)	0.06	—					
Cost associated with the decision to early terminate a European distributor arrangement in the Diagnostics segment (\$11 million or \$8 million after-tax)	0.04	—					
Gain from a cash distribution received from the sale of company, in which BD had a small equity ownership (\$8 million or \$5 million after-tax)	(0.03)	—					
Adjusted Diluted Earnings per Share from Continuing Operations	\$ 1.53	\$ 1.39	\$ 0.14	\$ (0.08)	\$ 0.22	10.1%	15.8%

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
FY2014 Year-to-Date Reconciliation of Non-GAAP Financial Measures  
(Unaudited)

	Six Months Ended March 31,						
	<u>2014</u>	<u>2013</u>	<u>Growth</u>	<u>Foreign Currency Translation</u>	<u>Foreign Currency Neutral Change</u>	<u>Growth %</u>	<u>Foreign Currency Neutral Growth %</u>
Reported Diluted Earnings per Share from Continuing Operations	\$ 2.82	\$2.74	\$ 0.08	\$ (0.17)	\$ 0.25	2.9%	9.1%
Write-off of capitalized product software and, to a lesser extent, fixed assets primarily resulting from the discontinuance of an instrument product development program in the Biosciences segment (\$20 million or \$12 million after-tax)	0.06	—					
Cost associated with the decision to early terminate a European distributor arrangement in the Diagnostics segment (\$11 million or \$8 million after-tax)	0.04	—					
Gain from a cash distribution received from the sale of company, in which BD had a small equity ownership (\$8 million or \$5 million after-tax)	(0.03)	—					
Adjusted Diluted Earnings per Share from Continuing Operations	\$ 2.90	\$2.74	\$ 0.16	\$ (0.17)	\$ 0.33	5.8%	12.0%
The incremental impact in first quarter fiscal year 2014 of the medical device excise tax which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act (\$14 million or \$9 million after-tax)	0.05	0.00					
Adjusted Diluted Earnings per Share from Continuing Operations without incremental first quarter fiscal year 2014 impact of Medical Device Excise Tax	\$ 2.94	\$2.74	\$ 0.20	\$ (0.17)	\$ 0.37	7.3%	13.5%

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
FY2014 Outlook Reconciliation

	Reported Basis	FX Impact	FXN Basis
Revenues - Full Year 2014 estimated growth	4.0% - 4.5%	(0.5%)	4.5% - 5.0%
	Full Year 2014 (estimated)	Full Year 2013	% Increase
Reported Fully Diluted Earnings per Share from Continuing Operations	\$6.14 - 6.17	\$ 4.67	NM
Write-off of capitalized product software and, to a lesser extent, fixed assets primarily resulting from the discontinuance of an instrument product development program in the Biosciences segment	0.06		
Cost associated with the decision to early terminate a European distributor arrangement in the Diagnostics segment	0.04		
Gain from a cash distribution received from the sale of company, in which BD had a small equity ownership	(0.03)		
Charge associated with the litigation settlement related to indirect purchaser antitrust class action cases		0.07	
Charge associated with the unfavorable verdict returned in the antitrust and false advertising lawsuit filed against the Company by RTI		1.06	
Non-cash pension settlement charge associated with lump sum benefit payments made from the Company's U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost for the year. The charge also included settlement losses associated with certain foreign pension plans.		0.02	
Adjusted Fully Diluted Earnings per Share from Continuing Operations	<u>\$6.22 - 6.25</u>	<u>\$ 5.81</u>	7.0% - 7.5%
FX Impact			(3.0%)
Adjusted FXN Growth			10.0% - 10.5%
Represents the incremental impact of the medical device excise tax in first quarter fiscal year 2014 (tax went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act)			(1.0%)
Adjusted FXN Growth (excluding the medical device excise tax)			11.0% - 11.5%

NM - Not Meaningful

FXN = Foreign Currency Neutral